- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04585009
Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics
June 16, 2023 updated by: GlaxoSmithKline
A Randomised Double-blind, Placebo Controlled, Single Ascending and Repeat Dose, First Time in Human Study in Healthy Participants and Stable Asthmatics to Assess Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder
This is a first time in human (FTIH) study designed to evaluate the safety, tolerability and pharmacokinetic (PK) profile of single and repeat doses of GSK3923868 inhalation powder in both healthy participants and asthmatics.
This is a 3-part, randomized, double blind, placebo controlled study of GSK3923868, administered as an inhalation powder blend (GSK3923868 capsules for inhalation) via Mono-dose inhaler in healthy participants (Parts A and B) and in participants with asthma (Part C).
The duration of study participation for each part A, B and C will be 11, 9 and 8 weeks, respectively.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
56
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cambridge, United Kingdom, CB2 2GG
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria: For Parts A and B
- Between 18 and 50 years of age inclusive, at the time of signing the informed consent.
- Participants who are generally healthy as determined by medical evaluation based on screening medical history, physical examination, vital signs, ECG assessment, pulmonary function testing, laboratory tests and cardiac monitoring.
- Body weight at least 50.0 kilograms (kg) (110 pounds [lbs]) and body mass index (BMI) within the range 18.5 to 32.0 kilograms per meter square (kg/m^2) (inclusive).
- Male Participants: A male participant is eligible to participate if they agree to the following during the intervention period and for at least 10 days after the last dose of study intervention: Refrain from donating sperm. Plus either be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remaining abstinent OR must agree to use contraception as detailed below when having sexual intercourse with a woman of childbearing potential who is not currently pregnant: Agree to use a male condom AND female partner to use an additional highly effective contraceptive method with a failure rate of < 1 percent per year. The participant should also be advised of the benefit for a female partner as a condom may break or leak.
- Female Participants: A female participant is eligible to participate if she is not pregnant or breastfeeding and is a woman of non-childbearing potential (WONCBP).
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and protocol.
Inclusion Criteria: Part C
- Between 18 and 50 years of age inclusive, at the time of signing the informed consent.
- Participants who are otherwise healthy (other than the acceptable condition of asthma and other mild atopic diseases, including allergic rhinitis and atopic dermatitis) as determined by medical evaluation based on screening medical history, physical examination, vital signs, ECG assessment, pulmonary function testing, laboratory tests and cardiac monitoring.
- A physician diagnosis of asthma (as defined by the Global Initiative for Asthma [GINA], 2020 guidelines) at least 6 months before screening. The reason for diagnosis of asthma should be documented in the participant's source data, including relevant history.
- A screening pre-bronchodilator FEV1 >= 65 percent predicted normal value.
- Positive bronchodilator reversibility test defined as an increase in FEV1 of > 12 percent and > 200 milliliter (mL) from Baseline, 10 to 15 minutes after administration of 400 micrograms (μg) salbutamol (or equivalent).
- Participants with maintained control of their asthma using the permitted medications: short-acting beta agonist (SABA) use only (n=8 participants) and regular treatment with inhaled corticosteroid (ICS) or ICS/long-acting beta agonist (LABA) (including use of Leukotriene Receptor Agonist [LTRA]) (n=8 participants).
- Body weight at least 50.0 kg (110 lbs) and BMI within the range 18.5 to 32.0 kg/m^2 (inclusive).
- Male Participants: A male participant is eligible to participate if they agree to the following during the intervention period and for at least 10 days after the last dose of study intervention: Refrain from donating sperm plus either be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remaining abstinent OR must agree to use contraception as detailed below when having sexual intercourse with a woman of childbearing potential who is not currently pregnant: Agree to use a male condom AND female partner to use an additional highly effective contraceptive method with a failure rate of < 1 percent per year. The participant should also be advised of the benefit for a female partner as a condom may break or leak.
- Female Participants: A female participant is eligible to participate if she is not pregnant or breastfeeding and is a WONCBP.
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
Exclusion Criteria: Part A and B
- History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
- Alanine transaminase (ALT) and Aspartate Aminotransferase (AST) above upper limit of normal (ULN).
- Total Bilirubin above ULN (isolated bilirubin above ULN is acceptable if total bilirubin is fractionated and direct bilirubin <35 percent).
- Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- QTcF > 450 milliseconds (msec) at screening visit based on the average of triplicate ECGs.
- Screening ECG measurements meets the following criteria for exclusion: heart rate: males- <45 or > 100 beats per minute (bpm); females- <50 or > 100 bpm; PR interval: <120 or >220 msec; QRS duration: <70 or >120 msec; QTcF: >450 msec.
- Medical history of cardiac arrhythmias or cardiac disease or a family or personal history of long QT syndrome.
- Evidence of previous myocardial infarction (does not include ST segment changes associated with re-polarization).
- Signs and symptoms suggestive of COVID-19.
- Past or intended use of over-the-counter or prescription medication, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days before the first dose of study intervention, unless in the opinion of the Investigator and the GlaxoSmithKline (GSK) Medical Monitor, the medication will not interfere with the study procedures or compromise participant safety.
- Participation in this study would result in loss of blood or blood products in excess of 500 milliliter (mL) within 56 days.
- Exposure to more than 4 new chemical entities within 12 months before the first dosing day.
- Current enrolment or past participation in a clinical trial and has received an investigational product within the following time period before the first dosing day in this study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- FEV1 and FVC is < 80 percent predicted normal value.
- Presence of hepatitis B surface antigen (HBsAg) at screening or within 3 months prior to first dose of study intervention.
- Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention.
- Positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention.
- Positive pre-study drug/alcohol screen.
- Positive human immunodeficiency virus (HIV) antibody test.
- Positive test for COVID-19 infection.
- Current or history of drug abuse.
- Any conduction abnormality (including but not specific to left or right complete bundle branch block, atrioventricular (AV) block [2nd degree or higher], Wolff-Parkinson-White (WPW) syndrome).
- Sinus Pauses > 3 seconds.
- Any significant arrhythmia which, in the opinion of the Investigator or GSK Medical monitor, will interfere with the safety for the individual participant.
- Non-sustained or sustained ventricular tachycardia (with more than 3 consecutive ventricular ectopic beats).
- Regular alcohol consumption within 6 months prior to the study defined as: an average weekly intake of > 14 units for both males and females. One unit is equivalent to 8 grams (g) of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
- Current or previous use of tobacco- or nicotine-containing products (e.g. cigarettes, nicotine patches or electronic devices) within 6 months before screening and/or have a smoking pack history of > 5 pack years.
- Positive breath carbon monoxide test indicative of recent smoking at screening or each in-house admission to the clinical research unit.
- Sensitivity to any of the study interventions, or components thereof (including lactose and magnesium stearate [MgSt]), or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
- Participants with known COVID-19 positive contacts in the past 14 days.
Exclusion criteria: Part C
- Any asthma exacerbation requiring systemic corticosteroids within 8 weeks of screening, or that resulted in overnight hospitalization requiring additional treatment for asthma within 3 months of screening.
- A history of life-threatening asthma, defined as an any asthma episode that required admission to a high-dependency or intensive therapy unit.
- Significant pulmonary diseases, other than asthma, including (but not limited to): pneumonia previously requiring hospital admission, bronchiectasis, pulmonary fibrosis, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, or other significant respiratory abnormalities.
- ALT and AST above ULN.
- Bilirubin above ULN (isolated bilirubin above ULN is acceptable if bilirubin is fractionated and direct bilirubin <35 percent).
- Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- QTcF > 450 msec at screening visit based on the average of triplicate ECGs.
- Signs and symptoms suggestive of COVID-19.
- Past or intended use of over-the-counter or prescription medication, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days before the first dose of study intervention, unless in the opinion of the Investigator and the GSK Medical Monitor, the medication will not interfere with the study procedures or compromise participant safety.
- Participation in this study would result in loss of blood or blood products in excess of 500 mL within 56 days.
- Exposure to more than 4 new chemical entities within 12 months before the first dosing day.
- Current enrolment or past participation in a clinical trial and has received an investigational product within the following time period before the first dosing day in this study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Presence of HBsAg at screening or within 3 months prior to first dose of study intervention.
- Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention.
- Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention.
- Positive pre-study drug/alcohol screen.
- Positive HIV antibody test.
- Positive test for COVID-19 infection.
- Current or history of drug abuse.
- Regular alcohol consumption within 6 months prior to the study defined as: an average weekly intake of > 14 units for males and females. One unit is equivalent to 8 g of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
- Current or previous use of tobacco- or nicotine-containing products (e.g. cigarettes, nicotine patches or electronic devices) within 6 months before screening and/or have a smoking pack history of > 5 pack years.
- Positive breath carbon monoxide test indicative of recent smoking at screening or each in-house admission to the clinical research unit.
- Sensitivity to any of the study interventions, or components thereof (including lactose and MgSt), or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
- Participants with known COVID-19 positive contacts in the past 14 days.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort1:GSK3923868 50 micrograms (mcg)/ Placebo/ 250mcg
Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 50 mcg/Placebo/250 mcg in treatment periods 1, 2 and 3 respectively.
There will be at least 10 days of wash-out period between doses for each participant.
|
GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.
Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
|
Experimental: Cohort 1:GSK3923868 50 mcg/ 100 mcg/ Placebo
Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 50 mcg/100 mcg/Placebo in treatment periods 1, 2 and 3 respectively.
There will be at least 10 days of wash-out period between doses for each participant.
|
GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.
Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
|
Experimental: Cohort 1:GSK3923868 50mcg/ 100mcg/ 250mcg
Healthy participants will receive single ascending doses of GSK3923868 in the planned treatment sequence: GSK3923868 50 mcg/100 mcg/250 mcg in treatment periods 1, 2 and 3 respectively.
There will be at least 10 days of wash-out period between doses for each participant.
|
GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
|
Experimental: Cohort 1:Placebo / GSK3923868 100 mcg/ GSK3923868 250 mcg
Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: Placebo/GSK3923868 100 mcg/GSK3923868 250 mcg in treatment periods 1, 2 and 3 respectively.
There will be at least 10 days of wash-out period between doses for each participant.
|
GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.
Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
|
Experimental: Cohort 2:Placebo / GSK3923868 1000 mcg/ GSK3923868 3000 mcg
Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: Placebo/GSK3923868 1000 mcg/GSK3923868 3000 mcg.
There will be at least 10 days of wash-out period between doses for each participant.
|
GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.
Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
|
Experimental: Cohort 2:GSK3923868 500 mcg/ Placebo/ 3000 mcg
Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 500 mcg/Placebo/3000 mcg.
There will be at least 10 days of wash-out period between doses for each participant.
|
GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.
Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
|
Experimental: Cohort 2:GSK3923868 500 mcg/ 1000 mcg/ Placebo
Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 500 mcg/1000 mcg/Placebo.
There will be at least 10 days of wash-out period between doses for each participant.
|
GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.
Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
|
Experimental: Cohort 2:GSK3923868 500mcg/ 1000mcg/ 3000mcg
Healthy participants will receive single ascending doses of GSK3923868 in the planned treatment sequence: GSK3923868 500 mcg/1000 mcg/3000 mcg.
There will be at least 10 days of wash-out period between doses for each participant.
|
GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
|
Experimental: Cohort 3: Participants receivings repeated doses of GSK3923868
Healthy participants will receive planned repeat doses of 3000 mcg (six capsules) GSK3923868 daily for 14 days
|
GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
|
Experimental: Cohort 4: Participants receiving repeat doses of GSK3923868
Healthy participants will receive planned repeat doses of 3000 mcg (six capsules) GSK3923868 daily for 14 days
|
GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
|
Experimental: Cohort 5: Participants receiving repeat doses of GSK3923868
Participants with stable asthma will receive a planned repeat dosing of 3000 mcg (six capsules) GSK3923868 daily for 7 days
|
GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A, Cohort-1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Up to Day 43
|
AEs and SAEs were collected.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.
A SAE is any untoward medical occurrence that, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity and/or can result in death.
Number of participants with AEs and SAEs assessed in Part A, Cohort-1 from the start of dosing and post-dose washout period (10 days) after treatment periods was reported.
|
Up to Day 43
|
Part A, Cohort 2: Number of Participants With AEs and SAEs
Time Frame: Up to Day 43
|
AEs and SAEs were collected.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.
A SAE is any untoward medical occurrence that, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity and/or can result in death.
Number of participants with AEs and SAEs assessed in Part A, Cohort-2 from the start of dosing and post-dose washout period (10 days) after treatment periods was reported.
|
Up to Day 43
|
Part B: Number of Participants With AEs and SAEs
Time Frame: Up to Day 28
|
AEs and SAEs were collected.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.
A SAE is any untoward medical occurrence that, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity and/or can result in death.
Number of participants with AEs and SAEs assessed in Part B, Cohort-3 and 4 (repeat dose) of the study were reported.
Part B assessed repeat doses of study drug across two parallel cohorts (Cohorts 3 and 4).
|
Up to Day 28
|
Part C: Number of Participants With AEs and SAEs
Time Frame: Up to Day 21
|
AEs and SAEs were collected.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.
A SAE is any untoward medical occurrence that, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity and/or can result in death.
Number of participants with AEs and SAEs assessed in Part C, Cohort-5 (repeat dose) of the study were reported.
|
Up to Day 21
|
Part A, Cohort-1: Number of Participants With Clinically Significant Changes in Clinical Chemistry and Hematology Laboratory Parameters
Time Frame: From start of the treatment (Day 1) to Day 2 in each treatment period
|
The laboratory (lab) measurements included Clinical chemistry and hematology.
The parameters evaluated were hemoglobin, leukocytes, lymphocytes/leukocytes, neutrophils/leukocytes, platelets, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, red blood cells, reticulocytes, Alanine Aminotransferase (ALT), Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Bilirubin, Calcium Corrected for Albumin, Creatinine, Glucose, Potassium and Sodium.
Number of participants with clinically significant changes from baseline in clinical chemistry and hematology were reported.
Clinical significance was determined by the investigator.
|
From start of the treatment (Day 1) to Day 2 in each treatment period
|
Part A, Cohort-2: Number of Participants With Clinically Significant Changes in Clinical Chemistry and Hematology Lab Parameters
Time Frame: From start of the treatment (Day 1) to Day 2 in each treatment period
|
The laboratory (lab) measurements included Clinical chemistry and hematology.
The parameters evaluated were hemoglobin, leukocytes, lymphocytes/leukocytes, neutrophils/leukocytes, platelets, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, red blood cells, reticulocytes, Alanine Aminotransferase (ALT), Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Bilirubin, Calcium Corrected for Albumin, Creatinine, Glucose, Potassium and Sodium.
Number of participants with clinically significant changes from baseline in clinical chemistry and hematology were reported.
Clinical significance was determined by the investigator.
|
From start of the treatment (Day 1) to Day 2 in each treatment period
|
Part B: Number of Participants With Clinically Significant Changes in Clinical Chemistry and Hematology Lab Parameters
Time Frame: From start of the treatment (Day 1) to Day 18
|
The laboratory (lab) measurements included Clinical chemistry and hematology.
The parameters evaluated were hemoglobin, leukocytes, lymphocytes/leukocytes, neutrophils/leukocytes, platelets, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, red blood cells, reticulocytes, Alanine Aminotransferase (ALT), Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Bilirubin, Calcium Corrected for Albumin, Creatinine, Glucose, Potassium and Sodium.
Part B assessed repeat doses of study drug across two parallel cohorts (Cohorts 3 and 4).
Number of participants with clinically significant changes from baseline in clinical chemistry and hematology were reported.
Clinical significance was determined by the investigator.
|
From start of the treatment (Day 1) to Day 18
|
Part C: Number of Participants With Clinically Significant Changes in Clinical Chemistry and Hematology Lab Parameters
Time Frame: From start of the treatment (Day 1) to Day 8
|
The laboratory (lab) measurements included Clinical chemistry and hematology.
The parameters evaluated were hemoglobin, leukocytes, lymphocytes/leukocytes, neutrophils/leukocytes, platelets, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, red blood cells, reticulocytes, Alanine Aminotransferase (ALT), Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Bilirubin, Calcium Corrected for Albumin, Creatinine, Glucose, Potassium and Sodium.
Number of participants with clinically significant changes from baseline in clinical chemistry and hematology were reported.
Clinical significance was determined by the investigator.
|
From start of the treatment (Day 1) to Day 8
|
Part A, Cohort-1: Number of Participants With Clinically Significant Changes in Vital Signs and 12-Lead Electrocardiogram (ECG) Findings
Time Frame: From start of the treatment (Day 1) to Day 2 in each treatment period
|
Vital signs included systolic and diastolic blood pressure, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest.
Temperature was also measured as a vital sign but did not require positioning or rest prior to measuring.
Twelve-lead electrocardiogram were performed in a semi-supine position using an ECG machine that automatically calculates the heart rate and measures PR interval, QRS duration, QT and corrected QT intervals (QTc) intervals.
Number of participants with clinically significant changes in parameters for cohort-1 were reported.
Clinical significance was determined by the investigator.
|
From start of the treatment (Day 1) to Day 2 in each treatment period
|
Part A, Cohort-2: Number of Participants With Clinically Significant Changes in Vital Signs and 12-Lead ECG Findings
Time Frame: From start of the treatment (Day 1) to Day 2 in each treatment period
|
Vital signs included systolic and diastolic blood pressure, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest.
Temperature was also measured as a vital sign but did not require positioning or rest prior to measuring.
Twelve-lead electrocardiogram were performed in a semi-supine position using an ECG machine that automatically calculates the heart rate and measures PR interval, QRS duration, QT and corrected QT intervals (QTc) intervals.
Number of participants with clinically significant changes in parameters for cohort-2 were reported.
Clinical significance was determined by the investigator.
|
From start of the treatment (Day 1) to Day 2 in each treatment period
|
Part B: Number of Participants With Clinically Significant Changes in Vital Signs and 12-Lead ECG Findings
Time Frame: From start of the treatment (Day 1) to Day 18
|
Vital signs included systolic and diastolic blood pressure, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest.
Temperature was also measured as a vital sign but did not require positioning or rest prior to measuring.
Twelve-lead electrocardiogram were performed in a semi-supine position using an ECG machine that automatically calculates the heart rate and measures PR interval, QRS duration, QT and corrected QT intervals (QTc) intervals.
Part B assessed repeat doses of study drug across two parallel cohorts (Cohorts 3 and 4).
Number of participants with clinically significant changes in parameters were reported.
Clinical significance was determined by the investigator.
|
From start of the treatment (Day 1) to Day 18
|
Part C: Number of Participants With Clinically Significant Changes in Vital Signs and 12-Lead ECG Findings
Time Frame: From start of the treatment (Day 1) to Day 8
|
Vital signs included systolic and diastolic blood pressure, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest.
Temperature was also measured as a vital sign but did not require positioning or rest prior to measuring.
Twelve-lead electrocardiogram were performed in a semi-supine position using an ECG machine that automatically calculates the heart rate and measures PR interval, QRS duration, QT and corrected QT intervals (QTc) intervals.
Number of participants with clinically significant changes in parameters for cohort-5 were reported.
Clinical significance was determined by the investigator.
|
From start of the treatment (Day 1) to Day 8
|
Part A, Cohort-1: Number of Participants With Clinically Significant Changes in Spirometry Measurements
Time Frame: From start of the treatment (Day 1) to Day 2 in each treatment period
|
Spirometry included forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) for lung function assessment.
Number of participants with clinically significant changes in parameters were reported.
Clinical significance was determined by the investigator.
|
From start of the treatment (Day 1) to Day 2 in each treatment period
|
Part A, Cohort-2: Number of Participants With Clinically Significant Changes in Spirometry Measurements
Time Frame: From start of the treatment (Day 1) to Day 2 in each treatment period
|
Spirometry included forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) for lung function assessment.
Number of participants with clinically significant changes in parameters were reported.
Clinical significance was determined by the investigator.
|
From start of the treatment (Day 1) to Day 2 in each treatment period
|
Part B: Number of Participants With Clinically Significant Changes in Spirometry Measurements
Time Frame: From start of the treatment (Day 1) up to Day 18
|
Spirometry included forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) for lung function assessment.
Number of participants with clinically significant changes in parameters were reported.
Clinical significance was determined by the investigator.
|
From start of the treatment (Day 1) up to Day 18
|
Part C: Number of Participants With Clinically Significant Changes in Spirometry Measurements
Time Frame: From start of the treatment (Day 1) to Day 8
|
Spirometry included forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) for lung function assessment.
Number of participants with clinically significant changes in parameters were reported.
Clinical significance was determined by the investigator.
|
From start of the treatment (Day 1) to Day 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A, Cohort 1 and 2: Area Under the Plasma GSK3923868 Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration (AUC[0-t])
Time Frame: Up to Day 2 in each treatment period
|
Blood samples were collected for measurement of plasma concentrations of GSK3923868.
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration values were reported.
Single ascending doses of GSK3923868 were assessed in 2 sequential crossover cohorts (Cohorts 1 and 2) of healthy participants, each with up to 3 treatment periods.
|
Up to Day 2 in each treatment period
|
Part A, Cohort 1 and 2: Area Under the Plasma GSK3923868 Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-inf])
Time Frame: Up to Day 2 in each treatment period
|
Blood samples were collected for measurement of plasma concentrations of GSK3923868.
Area under the concentration-time curve from time zero extrapolated to infinite time values were reported.
|
Up to Day 2 in each treatment period
|
Part A, Cohort 1 and 2: Maximum Observed GSK3923868 Plasma Concentration (Cmax)
Time Frame: Up to Day 2 in each treatment period
|
Cmax was defined as the maximum concentration of drug GSK3923868 in plasma.
Blood samples were collected for measurement of plasma concentrations of GSK3923868 for PK analysis.
|
Up to Day 2 in each treatment period
|
Part A, Cohort 1 and 2: Time to Maximum Observed Plasma Drug Concentration (Tmax)
Time Frame: Up to Day 2 in each treatment period
|
Tmax was defined as time required to achieve Cmax for drug GSK3923868 in plasma.
Blood samples were collected for measurement of plasma concentrations of GSK3923868 for PK analysis.
|
Up to Day 2 in each treatment period
|
Part B, Cohort 3 and 4: AUC From Time Zero (Predose) to Time Tau (AUC [0-tau]) (Tau=24hours for Once a Day Dosing Regimen) of GSK3923868
Time Frame: Up to Day 14
|
Blood samples were collected for measurement of plasma concentrations of GSK3923868 for PK analysis.
Area under the concentration-time curve from time zero (predose) to time tau (dosing interval) was reported.
Part B assessed repeat doses of study drug across two parallel cohorts (Cohorts 3 and 4).
|
Up to Day 14
|
Part B, Cohort 3 and 4: Cmax of GSK3923868
Time Frame: Up to Day 14
|
Cmax was defined as the maximum concentration of drug GSK3923868 in plasma.
Blood samples were collected for measurement of plasma concentrations of GSK3923868 for PK analysis.
Part B assessed repeat doses of study drug across two parallel cohorts (Cohorts 3 and 4).
|
Up to Day 14
|
Part B, Cohort 3 and 4: Tmax of GSK3923868
Time Frame: Up to Day 14
|
Tmax was defined as time required to achieve Cmax for drug GSK3923868 in plasma.
Blood samples were collected for measurement of plasma concentrations of GSK3923868 for PK analysis.
Part B assessed repeat doses of study drug across two parallel cohorts (Cohorts 3 and 4).
|
Up to Day 14
|
Part C: AUC (0-tau) (Tau=24 Hours for Once a Day Dosing Regimen) of GSK3923868
Time Frame: Up to Day 7
|
Blood samples were collected for measurement of plasma concentrations of GSK3923868 for PK analysis.
|
Up to Day 7
|
Part C: Cmax of GSK3923868
Time Frame: Up to Day 7
|
Cmax was defined as the maximum concentration of drug GSK3923868 in plasma.
Blood samples were collected for measurement of plasma concentrations of GSK3923868 for PK analysis.
|
Up to Day 7
|
Part C: Tmax of GSK3923868
Time Frame: Up to Day 7
|
Tmax was defined as time required to achieve Cmax for drug GSK3923868 in plasma.
Blood samples were collected for measurement of plasma concentrations of GSK3923868 for PK analysis.
|
Up to Day 7
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: GSK Clinical Trials, GlaxoSmithKline
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 12, 2020
Primary Completion (Actual)
June 16, 2022
Study Completion (Actual)
June 16, 2022
Study Registration Dates
First Submitted
October 9, 2020
First Submitted That Met QC Criteria
October 9, 2020
First Posted (Actual)
October 14, 2020
Study Record Updates
Last Update Posted (Actual)
February 20, 2024
Last Update Submitted That Met QC Criteria
June 16, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Immune System Diseases
- Respiration Disorders
- Lung Diseases
- Hypersensitivity, Immediate
- Disease Attributes
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Chronic Disease
- Pulmonary Disease, Chronic Obstructive
- Respiratory Aspiration
- Asthma
Other Study ID Numbers
- 213497
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
IPD for this study will be made available via the Clinical Study Data Request site.
IPD Sharing Time Frame
IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study
IPD Sharing Access Criteria
Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place.
Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on GSK3923868
-
GlaxoSmithKlineRecruitingPulmonary Disease, Chronic ObstructiveUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveGermany